5α-Reductase inhibitors (5ARIs) have shown efficacy in reducing hair loss and stimulating hair growth in men with androgenetic alopecia.

5ARIs are effective in women with hyperandrogenism and alopecia, with evidence also supporting their use in normoandrogenic postmenopausal women.

Topical formulation of 5ARIs reduces unwanted side effects and may improve patient adherence to treatment.

The application of 5ARIS for pharmacological treatment of acne vulgaris, hirsutism, and frontal fibrosing alopecia is promising, but requires further evaluation.